Cingulate Inc. Ttl Fee Amt
Cingulate Inc. (CING) had Ttl Fee Amt of $703.09 as of 2026-07-15, per its S-8 filed 2026-07-15.
Financial Statements › Notes
ffd:TtlFeeAmt · last filed 2026-07-15
- 2026-07-15: Ttl Fee Amt $703.09.
- 2026-04-14: Ttl Fee Amt $3.29K.
| Period end | Ttl Fee Amt |
|---|---|
| 2026-07-15 | $703.09 S-8 · filed 2026-07-15 |
| 2026-04-14 | $3.29K S-3 · filed 2026-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |